Table 3.
Main characteristics of 138 patients who completed the follow-up, according to cure criteria.
| Main Variables n = 117 | Cured = 111 | Uncured n = 6 | p-Value |
|---|---|---|---|
| Female gender | 48 (43.2%) | 3 (50%) | 0.7 |
| Age | 38.3 (SD 13.1) | 33.9 (SD 10.5) | 0.2 |
| Geographic area n = 117 | n = 111 | n = 6 | 0.06 |
| South America | 71 (64%) | 2 (33.3%) | |
| Central America and Caribbean | 6 (5.4%) | 1 (16.7%) | |
| North Africa | 4 (3.6%) | 0 | |
| Sub-Saharan Africa | 28 (25.3%) | 2 (33.3%) | |
| South-East Asia | 1(0.9%) | 1 (16.7%) | |
| Eastern Europe | 1 (0.9%) | 0 | |
| Immunosuppressed | 37 (30.6%) | 2 (28.6%) | 0.91 |
| Baseline serology titers | 4.3 (SD 3.9) | 5. (SD 3.1) | 0.15 |
| Other parasitic infections | 34 (29.1%) | 2 (28.6%) | 0.98 |
| Treatment provided included ivermectin (n = 124) | 117 (98.3%) | 7 (100%) | 0.64 |
| Time to visit in days | 210 (SD 82.9) | 232.5 (SD 107.1) | 0.8 |